FINWIRES · TerminalLIVE
FINWIRES

Oppenheimer Initiates EMCOR Group at Outperform With $1,100 Price Target

By

EMCOR Group (EME) has an average rating of overweight and mean price target of $1,000.14, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

Oppenheimer Initiates Vulcan Materials at Market Perform

Vulcan Materials (VMC) has an average rating of overweight and mean price target of $335.19, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$VMC
Research

Research Alert: Iclr: Q4 2025 Results Mixed After Long Delay; 2026 Guidance Headwinds

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ICON reported challenging Q4 results with sales of $2.11B (+2.5% Y/Y, $130M above consensus) but adjusted EPS of $2.52 fell $0.59 short of estimates and declined 26.5%. Full-year 2025 sales of $8.25B rose just 0.8%, while adjusted EBITDA margin contracted meaningfully to 18.6% (-180 bps), reflecting industry headwinds including elevated cancellations and pricing pressure. A bright spot was strong bookings momentum with $3.2B in Q4 gross wins supporting a robust 1.36 book-to-bill ratio, while the completed accounting investigation resulted in minimal revenue restatements of 0.8%-1.1% for 2023-2024 with no operational impact. For 2026, ICLR guided to revenue of $7.85B-$8.15B and EPS of $10.00-$11.00, representing declines of about 3% and 16%, respectively, at the midpoint. The guidance reflects continued near-term margin pressure and operational challenges, in our view, though management expressed confidence in large pharma spending recovery and improving biotech funding conditions.

$ICLR
Research

Research Alert: Hpq: Decent Q2, Driven By Price Increases; Fy 26 Guidance Largely Maintained

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:HP's Q2 FY 26 results exceeded consensus with revenue of $14.41B (+9% Y/Y) vs. $14.07B estimate and non-GAAP EPS of $0.86 (+21%) vs. $0.72 consensus, with operating margin of 7.5% up 20 bps. Personal Systems grew 13% driven entirely by price increases while units declined 7%, and operating margin expanded 70 bps to 5.2% despite elevated component costs. We believe AI PC momentum provides upside as shipments reached 44% of mix (up from 35% prior quarter), though we expect consumer demand destruction as prices rise with memory/CPU costs. Management maintained FY 26 guidance with non-GAAP EPS of $3.00 midpoint, down from $3.05 but improved versus prior commentary, and free cash flow of $2.9B. We see downside to estimates given component price volatility, as recent price-increase-driven growth is likely unsustainable medium-term while Printing continues structural decline with revenue down 2% despite maintaining strong 18.3% operating margins.

$HPQ